Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Vicor Aktie legt nach Ankündigung zweier neuer Chip-Fabriken deutlich zu (Investing.com DE) +++ VICOR Aktie +8,73%

REGENERON Aktie

 >REGENERON Aktienkurs 
676.9 EUR    -1.0%    (TradegateBSX)
Ask: 676.2 EUR / 9 Stück
Bid: 671.2 EUR / 9 Stück
Tagesumsatz: 149 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
REGENERON Aktie über LYNX handeln
>REGENERON Performance
1 Woche: -5,1%
1 Monat: -2,3%
3 Monate: +27,9%
6 Monate: +1,1%
1 Jahr: +40,1%
laufendes Jahr: +2,1%
>REGENERON Aktie
Name:  REGENERON PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US75886F1075 / 881535
Symbol/ Ticker:  RGO (Frankfurt) / REGN (NASDAQ)
Kürzel:  FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN
Index:  S&P500, Nasdaq100
Webseite:  https://www.regeneron.com..
Profil:  Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and met..
>Volltext..
Marktkapitalisierung:  73386.21 Mio. EUR
Unternehmenswert:  68743.11 Mio. EUR
Umsatz:  13377.86 Mio. EUR
EBITDA:  4049.52 Mio. EUR
Nettogewinn:  3727.7 Mio. EUR
Gewinn je Aktie:  36.09 EUR
Schulden:  2330.81 Mio. EUR
Liquide Mittel:  2123.62 Mio. EUR
Operativer Cashflow:  4031.35 Mio. EUR
Bargeldquote:  1.45
Umsatzwachstum:  12.73%
Gewinnwachstum:  0.14%
Dividende je Aktie:  3.18 EUR
Dividendenrendite:  0.45%
Dividendenschätzung:  0.47%
Div. Historie:  18.08.26 - 0.80548596€
20.05.26 - 0.808306€
>weitere anzeigen...
Insiderhandel:  3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 2.845.217 Euro.
Suchwörter:  REGENERON
Letzte Datenerhebung:  11.09.26
>REGENERON Kennzahlen
Aktien/ Unternehmen:
Aktien: 101.14 Mio. St.
Frei handelbar: 97.99%
Leerverk. Aktien: 2.52%
Rückkaufquote: 2.98%
Mitarbeiter: 15410
Umsatz/Mitarb.: 0.8 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 2.68%
Bewertung:
KGV: 20.08
KGV lG: 15.24
KUV: 5.62
KBV: 2.65
PEG-Ratio: 10.41
EV/EBITDA: 16.98
Rentabilität:
Bruttomarge: 81.46%
Gewinnmarge: 27.86%
Operative Marge: 26.87%
Managementeffizenz:
Gesamtkaprendite: 10.83%
Eigenkaprendite: 14.04%
>REGENERON Peer Group
 
10.09.26 - 18:00
 REGN 4-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
10.09.26 - 16:48
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN (PR Newswire)
 
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or......
10.09.26 - 16:15
 SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN (PR Newswire)
 
Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FDA Otptimus-related amendments on progression-free survival analysis. NEW YORK, Sept. 10,......
10.09.26 - 13:57
 Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Regeneron to Contact Him Directly to Discuss Their Options NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds......
10.09.26 - 02:18
 REGN MONDAY DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit (PR Newswire)
 
SAN DIEGO, Sept. 9, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until September 14,......
09.09.26 - 23:03
 REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure (PR Newswire)
 
SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
09.09.26 - 16:48
 Regeneron auf Wells-Fargo-Konferenz: Wachstum auf breiterer Basis (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
09.09.26 - 16:15
 Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN (PR Newswire)
 
Institutional investors with REGN positions may need to assess alleged clinical-trial disclosure failures that preceded a $102.09 per-share decline from the Class Period high. This notice focuses on fiduciary review, portfolio loss documentation, and lead plaintiff considerations. NEW......
09.09.26 - 13:06
 Recent Stanton graduate wins Humane Science Award from National Anti-Vivisection Society (PR Newswire)
 
Alan Alwakeel among five young scientists worldwide to earn a $3,000 prize at 2026 Regeneron International Science and Engineering Fair JACKSONVILLE, Fla., Sept. 9, 2026 /PRNewswire/ -- Alan Alwakeel, a recent graduate of Stanton College Preparatory School in Jacksonville, Florida, was......
07.09.26 - 19:21
 REGN 1-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
04.09.26 - 21:00
 Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? (Fool)
 
They could both outperform the market over the medium term, but one appears to have a clear edge....
04.09.26 - 03:01
 Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 340000 USD (Insiderkauf)
 
Guarini, Kathryn - Aufsichtsrat - Tag der Transaktion: 2026-09-02...
04.09.26 - 03:01
 Insiderhandel: EVP Commercial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 969708 USD (Insiderkauf)
 
Mccourt, Marion - Vorstand - Tag der Transaktion: 2026-09-03...
04.09.26 - 03:01
 Insiderhandel: EVP Commercial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 1032750 USD (Insiderkauf)
 
Mccourt, Marion - Vorstand - Tag der Transaktion: 2026-09-02...
04.09.26 - 01:12
 REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit (PR Newswire)
 
SAN DIEGO, Sept. 3, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until September 14, 2026 to seek......
03.09.26 - 21:21
 REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure (PR Newswire)
 
SAN FRANCISCO, Sept. 3, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
03.09.26 - 16:09
 REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt (PR Newswire)
 
Market impact notice: REGN shares allegedly lost $102.09 from the Class Period high after disclosures about a Phase III Fianlimab-Libtayo protocol change and failed primary endpoint challenged earlier positive trial-risk messaging. NEW YORK, Sept. 3, 2026 /PRNewswire/ -- SueWallSt......
02.09.26 - 16:15
 REGN Deadline Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026 (PR Newswire)
 
Important Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial Risk Misrepresentations. The lawsuit alleges Regeneron investors overpaid while the Company characterized slowing event accrual as potentially favorable, even as the study allegedly faced heightened risk of......
01.09.26 - 18:24
 INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline (PR Newswire)
 
SAN FRANCISCO, Sept. 1, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
28.08.26 - 18:09
 Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline (PR Newswire)
 
SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Principiis consentit exitus - Den Anfängen entspricht der Ausgang. - Marcus Tullius Cicero
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!